WALTHAM, Mass., April 4, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing ...

WALTHAM, Mass., March 27, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing ...

Leerink initiated coverage of Spyre Therapeutics (SYRE) with an Outperform rating and $45 price target Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter ...

Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com .

NASDAQ:SYRE opened at $11.80 on Tuesday. The firm’s fifty day simple moving average is $19.28 and its 200-day simple moving average is $24.71. The stock has a market cap of $711.03 million, a PE ...

Wellington Management Group LLP increased its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 6.5% during the fourth quarter, Holdings Channel.com reports.

WASHINGTON — Gary Shapley, who became a folk hero to conservatives when he revealed the Justice Department played favorites in its investigation of former first son Hunter Biden, was ousted from ...

During the 2025 NFL Draft cycle, one of the biggest questions has been what position NFL teams will have Colorado two-way star Travis Hunter play in the pros. Hunter answered the question for them.

Andrew Berry has often referred to Travis Hunter as a unicorn. On Thursday, the Browns general manager went one step further and compared the Heisman Trophy winner to reigning National League MVP ...